• Specialties

    Hematologic malignancies

  • Departments

My Contact Information

More About Me

I am a physician-scientist with combined training in cancer biology and clinical medicine. My research focuses on the development of immune effector cell therapies for cancer. I also maintain an active clinic for patients with benign or malignant hematologic conditions. I joined BMC in 2021 as founding Director of the Cellular Therapy Program, whose core mission is to enable equitable patient access to innovative and powerful cancer cell therapies such as CAR T. Overall, I have 15+ years of hematology/oncology experience. I completed my MD and oncology training in Italy and then did a fellowship in cancer biology at Harvard. I was on the Harvard faculty for 2 years prior to joining BUSM sponsored by a NIH grant. For 4 years, I worked in industry as Medical Director of investigational CAR T cell therapies for various hematologic malignancies, including ide-cel approved for multiple myeloma in 2021. I am currently a full-time faculty at BUSM and an Attending Physician at BMC.
  • Administrative Title

    Director of Cellular Therapy Program, Assistant Professor of Medicine
  • Residency

    Oncology, University of Ferrara, Italy
  • Fellowship

    Research Fellowship, Program in Cellular and Molecular Medicine, Harvard Medical School, Boston, MA
  • Board Certifications

    Oncology (Italy)
  • Special Interests

    Hematologic malignancies
  • Languages


My Publications

  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
  2. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
  3. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

    BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment.
  4. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

    Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. In this case report, we detail the successful treatment of a relapsed and refractory multiple myeloma (MM) patient treated with an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy immediately following clinical recovery from COVID-19.


Boston University

Boston University is a leading private research institution with two primary campuses in the heart of Boston and programs around the world.

See my Boston University profile

Latest from HealthCity